ArticleLife sciences2009
Protein kinases C isozymes are differentially expressed in human breast carcinomas.
Article in Life sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer.Cancers · 2022Review
- Protein Kinase C Life Cycle: Explained Through Systems Biology Approach.Frontiers in physiology · 2022Article
- Protein Kinase C Alpha (PKCα) overexpression leads to a better response to retinoid acid therapy through Retinoic Acid Receptor Beta (RARβ) activation in mammary cancer cells.Journal of cancer research and clinical oncology · 2020Article
- Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.Leukemia · 2015Article
- The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.Oncotarget · 2015Article
- Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis.Frontiers in oncology · 2014Article
- Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.Molecular cancer · 2013Article
- Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.British journal of cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimsThe protein kinase C (PKC) family of enzymes has been implicated in cellular proliferation, differentiation, and apoptosis. However, the distribution of specific PKC isoforms with varying functions in normal and malignant human tissues remains to be determined. The objective of this study was to investigate the expression of certain PKC isoforms (alpha, betaI, betaII, epsilon) in human breast cancer specimens relative to adjacent uninvolved tissue (n=24) and in the normal breast tissue obtained from patients undergoing reduction mammoplasty (n=12). MAIN
methodsWestern blot analysis using PKC isoform specific antibodies was performed on tissue extracts from breast tumors, adjacent uninvolved tissues, and reduction mammoplasty tissues. KEY
findingsMean levels of cytosolic and membrane PKC-alpha, PKC-betaI, and PKC-betaII were significantly higher in the cancer specimens than in the adjacent uninvolved breast tissues (Wilcoxon signed-ranks test; P<0.05 for each, after adjustment for multiple comparisons). There was a notably higher mean level of membrane PKC-betaII isozyme in Her-2 positive and in poorly differentiated tumors. No significant differences were observed when normal tissue adjacent to tumor was compared to breast tissue obtained from reduction mammoplasty specimens. SIGNIFICANCE: Higher level of PKC-alpha, PKC-betaI, and PKC-betaII in cancer specimens and higher level of PKC-betaII in Her-2 positive tumors require further exploration of the intracellular pathways involving PKC-alpha and -beta isoforms in breast cancer because both could be specific targets for the development of new therapies and for the prevention and treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.